Phio Pharmaceuticals Corp (NASDAQ:PHIO) does about 367.04K shares in volume on a normal day but saw 280143636 shares change hands in the recent trading day. The company now has a market cap of 11.44M USD. Its current market price is $6.60, marking an increase of 290.53% compared to the previous close of $1.69. The 52 week high reached by this stock is $10.35 whilst the lowest price level in 52 weeks is $1.53.
Phio Pharmaceuticals Corp (PHIO) has a 20-day trading average at $2.3400 and the current price is -36.23% off the 52-week high compared with 331.37% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.5800 and its 200-day simple moving average is $4.2300. If we look at the stock’s price movements over the week, volatility stands at 34.42%, which decreases to 22.72% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 83.90 to suggest the stock is overbought.
The consensus objective for the share price is $36.00, suggesting that the stock has a potential upside of 81.67% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on August 05, 2020 when H.C. Wainwright initiated the stock to “Buy” and issued a price target of $4.
The current price level is 181.56%, 155.66%, and 56.14% away from its SMA20, SMA50, and SMA200 respectively, with the PHIO price moving below the 50-day SMA on current market day. Phio Pharmaceuticals Corp (PHIO) stock is up 235.03% over the week and 134.88% over the past month. Its price is 266.67% year-to-date and 0.95% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year.
To reach the target analysts have set, the stock logically needs to grow 81.67 percent from here.
Outstanding shares total 1.73M with insiders holding 4.81% of the shares and institutional holders owning 3.02% of the company’s common stock. The company has a return on investment of -150.00% and return on equity of -122.03%. The beta has a value of 1.51. Price to book ratio is 1.28.
